Platinum-based compounds are widely used and effective chemotherapeutic agents; however, sensory peripheral neuropathy is a dose-limiting and long term side effect for 20-30% of patients. A critical question is whether the mechanisms of cell death underlying clinical efficacy can be separated from the effects on neurons in order to develop strategies that prevent platinum-induced neuropathy. In rodent dorsal root ganglion neurons (DRG), cisplatin has been shown to bind and damage neuronal DNA, inducing apoptosis; however genetic manipulation in order to study mechanisms of this phenomenon in the rodent model system is costly and time-consuming. Drosophila melanogaster are commonly used to study neurological disorders, have DNA damage-apoptosis mechanisms homologous to mammalian systems, and have readily-available, inexpensive tools for rapid genetic manipulation. We therefore sought to develop adult Drosophila as a new model to study cisplatin-induced neurotoxicity. Adult Drosophila were exposed to 10, 25, 50, 100, 200 and 400 μg/ml cisplatin for 3 days and observed for fly survival and geotactic climbing behavior, cisplatin-DNA binding and cellular apoptosis. On day 3, 50 μg/ml cisplatin reduced the number of flies able to climb above 2 cm to 43% while fly survival was maintained at 92%. 100% lethality was observed at 400 μg/ml cisplatin. Whole fly platinum-genomic DNA adducts were measured and found to be comparable to adduct levels previously measured in rat DRG neurons. Brain, ovaries, kidney and heart harvested from cisplatin treated flies were stained for active caspase 3. Apoptosis was found in ovaries and brain but not in heart and kidney. Brain apoptosis was confirmed by transmission electron microscopy. Expression of the anti-apoptotic baculoviral protein, p35, in neurons using the GAL4-UAS system prevented cisplatin-induced apoptosis in the brain and restored climbing behavior. In conclusion, cisplatin-induced behavioral and apoptotic changes in Drosophila resemble those seen in mammals. Furthermore, the use of lethality and climbing assays combined with powerful gene manipulation, make Drosophila a suitable model to study mechanisms of cisplatin neurotoxicity.
Introduction
Chemotherapy induced peripheral neuropathy is a serious, life long side effect that impairs quality of life for long-term cancer survivors. Cisplatin and oxaliplatin are used to treat ovarian, testicular and metastatic colorectal cancers. Unfortunately, platinum drugs induce neuropathy in 20-30% of patients, which is the dose-limiting side effect (Thompson et al., 1984; Cavaletti, 2008; Windebank and Grisold, 2008) . Mammalian models have been developed to investigate the mechanisms of platinum-induced neurotoxicity (Cavaletti et al., 1998; Carozzi et al., 2010b; Carozzi et al., 2010a) . Cisplatin and oxaliplatin induce sensory behavioral changes in mice, in vivo (Ta et al., 2009 ). Mice treated with cisplatin exhibit thermal hyperalgesia to heat stimuli and mechanical allodynia. The chemotherapeutic mechanism of cisplatin and oxaliplatin is through DNA binding, inducing DNA damage that leads to apoptosis. Likewise, data from mammalian in vitro and in vivo models have demonstrated that sensory neurons undergo cisplatininduced apoptosis through a DNA damage mechanism that is similar to the mechanisms observed in cancer cells (Fischer et al., 2001; McDonald and Windebank, 2002; McDonald et al., 2005; Ta et al., 2006) .
Drosophila melanogaster have been used to study the genetics of human neurodegenerative diseases (Feany, 2010) . In Parkinson's disease (PD), mutations in Drosophila parkin and PINK1 have been linked to the mitochondrial pathology of PD. Expression of human α-synuclein in Drosophila using the GAL4-UAS system induces a PD phenotype and allows for the study of toxicity induced by α-synuclein aggregation (Botella et al., 2009 ). Alzheimer's disease can be modeled in transgenic Drosophila expressing genes which induce the production of amyloid-ß peptide. Aggregation of amyloid-ß is observed in these flies along with age related neurodegeneration and memory loss (Iijima and Iijima-Ando, 2008) . Neurobiology of Disease 43 (2011) 330-337 
